JP2023501781A - シェーグレン症候群の処置 - Google Patents

シェーグレン症候群の処置 Download PDF

Info

Publication number
JP2023501781A
JP2023501781A JP2022525650A JP2022525650A JP2023501781A JP 2023501781 A JP2023501781 A JP 2023501781A JP 2022525650 A JP2022525650 A JP 2022525650A JP 2022525650 A JP2022525650 A JP 2022525650A JP 2023501781 A JP2023501781 A JP 2023501781A
Authority
JP
Japan
Prior art keywords
antibody
administered
baffr
functional fragment
syndrome
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022525650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023501781A5 (https=
Inventor
バルトシェバ，イリナ
ヒュベール，ウォルフギャング
オリバー，ステファン
ペトリコウル，オリヴィエ
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023501781A publication Critical patent/JP2023501781A/ja
Publication of JP2023501781A5 publication Critical patent/JP2023501781A5/ja
Priority to JP2025225960A priority Critical patent/JP2026062653A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022525650A 2019-11-06 2020-10-23 シェーグレン症候群の処置 Pending JP2023501781A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025225960A JP2026062653A (ja) 2019-11-06 2025-12-03 シェーグレン症候群の処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962931292P 2019-11-06 2019-11-06
US62/931,292 2019-11-06
PCT/US2020/057184 WO2021091706A1 (en) 2019-11-06 2020-10-23 Treatment for sjögren's syndrome

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025225960A Division JP2026062653A (ja) 2019-11-06 2025-12-03 シェーグレン症候群の処置

Publications (2)

Publication Number Publication Date
JP2023501781A true JP2023501781A (ja) 2023-01-19
JP2023501781A5 JP2023501781A5 (https=) 2023-10-11

Family

ID=73449232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525650A Pending JP2023501781A (ja) 2019-11-06 2020-10-23 シェーグレン症候群の処置
JP2025225960A Pending JP2026062653A (ja) 2019-11-06 2025-12-03 シェーグレン症候群の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025225960A Pending JP2026062653A (ja) 2019-11-06 2025-12-03 シェーグレン症候群の処置

Country Status (7)

Country Link
US (1) US20220356261A1 (https=)
EP (1) EP4055047A1 (https=)
JP (2) JP2023501781A (https=)
KR (1) KR20220093347A (https=)
AU (2) AU2020377872B2 (https=)
CA (1) CA3160207A1 (https=)
WO (1) WO2021091706A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021320129B2 (en) * 2020-08-04 2025-12-18 Novartis Ag Treatment of B cell malignancies
WO2025083621A1 (en) * 2023-10-20 2025-04-24 Novartis Ag Treatment of hidradenitis suppurativa using anti-baff-r antibodies
WO2025257781A1 (en) * 2024-06-14 2025-12-18 Novartis Ag Treatment of systemic sclerosis using anti-baff-r antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507555A (ja) * 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド シェーグレン症候群の治療方法
US20180064828A1 (en) * 2012-09-25 2018-03-08 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Methods for the diagnosis and treatment of sjögren's syndrome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
TWI694836B (zh) * 2014-05-16 2020-06-01 英商葛蘭素史克智慧財產管理有限公司 抗體調配物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507555A (ja) * 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド シェーグレン症候群の治療方法
US20180064828A1 (en) * 2012-09-25 2018-03-08 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Methods for the diagnosis and treatment of sjögren's syndrome

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SMOLEN J. ET AL.: "Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell De", ARTHRITIS RHEUMATOL, vol. 71 (suppl 10), JPN6024035620, 23 October 2019 (2019-10-23), pages 19, ISSN: 0005807049 *

Also Published As

Publication number Publication date
AU2020377872A1 (en) 2022-05-26
AU2020377872B2 (en) 2025-04-24
JP2026062653A (ja) 2026-04-10
KR20220093347A (ko) 2022-07-05
EP4055047A1 (en) 2022-09-14
WO2021091706A1 (en) 2021-05-14
AU2025202534A1 (en) 2025-05-01
US20220356261A1 (en) 2022-11-10
CA3160207A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
AU2022201336B2 (en) Methods for treating nasal polyposis by administering an IL-4R antagonist
US11214621B2 (en) Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
JP7484027B2 (ja) 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2026062653A (ja) シェーグレン症候群の処置
EA037960B1 (ru) Способ лечения эозинофильного эзофагита с применением антитела против il-13
US20200048337A1 (en) Pharmaceutical composition for safe and effective treatment of knee and/or hip pain
CN114786775A (zh) 通过施用il-33拮抗剂治疗copd的方法
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
US20250066467A1 (en) Methods for the treatment of myasthenia gravis
KR20240014601A (ko) 화농성 한선염 치료를 위한 범-elr+ cxc 케모카인 항체
JP2024516019A (ja) 抗ｂａｆｆｒ抗体を使用する全身性エリテマトーデスのための治療
JP2025537966A (ja) 潰瘍性大腸炎を治療する方法
HK40072292A (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
CN117157099A (zh) 用于皮下注射的抗ifnar1给药方案
EA047082B1 (ru) Схема введения дозы антитела к ifnar 1 для подкожной инъекции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260303